Michael P. East

Michael P. East

Auto-generated profile, based on publicly available information

Michael P. East

University of North Carolina at Chapel Hill 2 Department of Pharmacology Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Cancer Discovery
Verified
Journal Article
Closed access
YXYi Xu
Yi Xu
XPXianlu Laura Peng
Xianlu Laura Peng
MEMichael P. East
Michael P. East
IMIan C. McCabe
Ian C. McCabe
GSGrace C. Stroman
Grace C. Stroman
JYJen Jen Yeh
Jen Jen Yeh
Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have been largely elusive. In this study, we perform multiplexed kinase inhibitor bead mass spectrometry on 102 patient-derived xenografts derived from 14 unique primary PDACs to define the tumor-intrinsic kinome landscape. Our findings uncover three kinome subgroups making up two tumor-intrinsic kinome subtypes that we call kinotypes. The kinotypes show enrichment of different kinase classes and recapitulate previously described molecular subtypes, basal-like and classical. The kinotype characterizing basal-like tumors shows enrichment of receptor tyrosine kinases, whereas the kinotype characterizing classical tumors is enriched in understudied kinases involved in Wnt signaling and immune pathways. We validate our findings in two clinical trials and show that only patients with basal-like tumors derive significant benefit from EGFR inhibitors. Our results provide a comprehensive tumor-intrinsic kinome landscape of PDAC that strongly supports actionable kinotype-specific kinase targets and provides a roadmap for kinase inhibitor therapy in PDAC. Significance: We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.

5 February 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
SMSmita Matkar
Smita Matkar
MEMichael P. East
Michael P. East
TSTimothy J. Stuhlmiller
Timothy J. Stuhlmiller
GWGabriela M. Witek
Gabriela M. Witek
AFAlvin Farrel
Alvin Farrel
YMYael P. Mossé
Yael P. Mossé
Mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first- and second-generation ALK inhibitors, including crizotinib and ceritinib. Lorlatinib, a third-generation ALK/ROS1 inhibitor, overcomes de novo resistance and induces complete and sustained tumor regressions in patient-derived xenograft models unresponsive to crizotinib. Lorlatinib has now completed phase 1 testing in children and adults with relapsed/refractory ALK-driven neuroblastoma and entered pivotal phase 3 testing within the Children’s Oncology Group. To define mechanisms underlying the superior activity of lorlatinib, we utilized a chemical proteomics approach to quantitatively measure functional kinome dynamics in response to lorlatinib and crizotinib in clinically relevant ALK-driven neuroblastoma patient-derived xenograft models. Lorlatinib was a markedly more potent inhibitor of ALK and preferentially downregulated several kinases implicated in G2/M cell-cycle transition compared with crizotinib. Lorlatinib treatment also led to the repression of MYCN expression and its occupancy at promoters of the same G2/M kinases. These data provide mechanistic insight into the superior efficacy of lorlatinib over crizotinib for the treatment of ALK-driven neuroblastoma.

9 May 2022 in ChemMedChem
Verified
Journal Article
Closed access
CAChristopher R. M. Asquith
Christopher R. M. Asquith
LTLouisa Temme
Louisa Temme
MEMichael P. East
Michael P. East
TLTuomo Laitinen
Tuomo Laitinen
JPJulie Pickett
Julie Pickett
David DrewryDavid Drewry
David Drewry

1 April 2020 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Open access
DODenis O. Okumu
Denis O. Okumu
LALucas J. Aponte-Collazo
Lucas J. Aponte-Collazo
BDBrian J. Dewar
Brian J. Dewar
NCNathan J. Cox
Nathan J. Cox
MEMichael P. East
Michael P. East
LGLee Graves
Lee Graves
Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellular creatine pools compared to imatinib-sensitive Myl cells. Stable isotope metabolic labeling, media creatine depletion, and Na+/K+-ATPase inhibitor experiments were performed to investigate the origin of creatine pools in Myl-R cells. Inhibition and shRNA knockdown were performed to investigate the specific role of Lyn in regulating the Na+/K+-ATPase and creatine uptake. Inhibition of the Na+/K+-ATPase pump (ouabain, digitoxin), depletion of extracellular creatine or inhibition of Lyn kinase (ponatinib, dasatinib), demonstrated that enhanced creatine accumulation in Myl-R cells was dependent on uptake from the growth media. Creatine uptake was independent of the Na+/creatine symporter (SLC6A8) expression or de novo synthesis. Western blot analyses showed that phosphorylation of the Na+/K+-ATPase on Tyr 10 (Y10), a known regulatory phosphorylation site, correlated with Lyn activity. Overexpression of Lyn in HEK293 cells increased Y10 phosphorylation (pY10) of the Na+/K+-ATPase, whereas Lyn inhibition or shRNA knockdown reduced Na+/K+-ATPase pY10 and decreased creatine accumulation in Myl-R cells. Consistent with enhanced uptake in Myl-R cells, cyclocreatine (Ccr), a cytotoxic creatine analog, caused significant loss of viability in Myl-R compared to Myl cells. These data suggest that Lyn can affect creatine uptake through Lyn-dependent phosphorylation and regulation of the Na+/K+-ATPase pump activity. These studies identify kinase regulation of the Na+/K+-ATPase as pivotal in regulating creatine uptake and energy metabolism in cells.

6 October 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
AWAustin A. Whitman
Austin A. Whitman
RKRasha Kakati
Rasha Kakati
SHSantiago Haase
Santiago Haase
CTChristine H.N.C. Thai
Christine H.N.C. Thai
STSurya Kant Tripathi
Surya Kant Tripathi
PSPhilip M Spanheimer
Philip M Spanheimer
Resistance to endocrine therapy (ET) is common in estrogen receptor–positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient-derived organoids (PDO). Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen-responsive luminal A–like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor bead–mass spectrometry revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Cotreatment with the HER2 inhibitor lapatinib further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ PDO and patient-derived xenograft models. Future studies should evaluate whether signatures predict responses in patients with ER+ breast tumors and determine the role of cotargeting HER2 signaling with vandetanib therapy.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RKRasha Kakati
Rasha Kakati
AWAustin A. Whitman
Austin A. Whitman
SHSantiago Haase
Santiago Haase
ASAttila T. Szenasi
Attila T. Szenasi
CTChristine Hnc Thai
Christine Hnc Thai
PSPhilip M Spanheimer
Philip M Spanheimer
Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient derived organoids. Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen responsive, Luminal-A like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor beads-mass spectrometry (MIB/MS) revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Co-treatment with the HER2 inhibitor lapatinib, further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex-vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ patient-derived organoid and xenograft models. Future clinical trials of vandetanib in ER+ breast cancer should include rationally designed co-treatments based on adaptive resistance pathways, including HER2, and evaluate response signatures as biomarkers predicting patients most likely to benefit. SIGNIFICANCE: Vandetanib enhances sensitivity to tamoxifen in ER+ breast cancer by reprograming ERα gene regulation and kinase signaling networks which define gene expression signatures associated with response and identify targetable adaptive resistance pathways.